Phase III randomized double-blind placebo-controlled multi-centre study assessing the efficacy and safety of durvalumab versus placebo as treatment following SBRT in patients with Stage I/II non small cell lung cancer.



If you are registered as a volunteer, please login to the dashboard to send referrals.